A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
Completed · Phase 3 · NCT03879135
Conditions: Von Willebrand Disease (VWD)
At a glance
- Research payments reported, 2025
- $66,261
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 38
About the trial
- Sponsor
- Baxalta now part of Shire (with Takeda Development Center Americas, Inc.)
- Tested
- rVWF (biological), rFVIII (biological)
- Dates
- Started 2019-04-01; completion 2025-01-30
- Results posted
- Yes
The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (not related to trauma) bleeding episodes in pediatric and adult participants during the first 12 months on study treatment. The participants will be treated with rVWF for a maximum of 3 years. Their von Willebrand Disease will be treated according to Investigational product (IP) dosing directions.
From ClinicalTrials.gov, last updated 2025-09-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $66,261 in research payments for this study in 2025 (31 payments).
Products named: Vonvendi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael Wang, MD Pediatric Hematology & Oncology · Aurora, CO
- Sanjay P. Ahuja, MD Pediatric Hematology & Oncology · Indianapolis, IN
- Amy D. Shapiro, MD Pediatric Hematology & Oncology · Indianapolis, IN
- Amy D. Dunn, MD Pediatrics · West Bloomfield, MI
- Eric Mullins, MD Pediatric Hematology & Oncology · Cincinnati, OH
- Shayla Bergmann, MD Pediatric Hematology & Oncology · Beaufort, SC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Musc Medical Center, SC $37,141
- The Research Institute at Nationwide $12,889
- Uh Cleveland Medical Center, OH $4,729
- Indiana Hemophilia and Thrombosis Center Inc $4,542
- Cincinnati Children's Hospital Medical Center, OH $3,995
- University of Colorado Hospital Authority, CO $2,965
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.